Lukas Minus Orre

Lukas Minus Orre

Auto-generated profile, based on publicly available information

Lukas Minus Orre

Department of Oncology and Pathology, Karolinska Institutet, SciLifeLab, Solna, Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
YZYafeng Zhu
Yafeng Zhu
LOLukas M. Orre
Lukas M. Orre
YTYan Zhou Tran
Yan Zhou Tran
GMGeorgios Mermelekas
Georgios Mermelekas
HJHenrik J. Johansson
Henrik J. Johansson
JLJanne Lehtiö
Janne Lehtiö
Quantitative proteomics by mass spectrometry is widely used in biomarker research and basic biology research for investigation of phenotype level cellular events. Despite the wide application, the methodology for statistical analysis of differentially expressed proteins has not been unified. Various methods such as t test, linear model and mixed effect models are used to define changes in proteomics experiments. However, none of these methods consider the specific structure of MS-data. Choices between methods, often originally developed for other types of data, are based on compromises between features such as statistical power, general applicability and user friendliness. Furthermore, whether to include proteins identified with one peptide in statistical analysis of differential protein expression varies between studies. Here we present DEqMS, a robust statistical method developed specifically for differential protein expression analysis in mass spectrometry data. In all data sets investigated there is a clear dependence of variance on the number of PSMs or peptides used for protein quantification. DEqMS takes this feature into account when assessing differential protein expression. This allows for a more accurate data-dependent estimation of protein variance and inclusion of single peptide identifications without increasing false discoveries. The method was tested in several data sets including E. coli proteome spike-in data, using both label-free and TMT-labeled quantification. Compared with previous statistical methods used in quantitative proteomics, DEqMS showed consistently better accuracy in detecting altered protein levels compared with other statistical methods in both label-free and labeled quantitative proteomics data. DEqMS is available as an R package in Bioconductor.

22 July 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
RVRosanne E. Veerman
Rosanne E. Veerman
LTLoes Teeuwen
Loes Teeuwen
PCPaulo Czarnewski
Paulo Czarnewski
GAGözde Güclüler Akpinar
Gözde Güclüler Akpinar
ASAnnSofi Sandberg
AnnSofi Sandberg
MEMaria Eldh
Maria Eldh
Extracellular vesicles (EVs) are increasingly tested as therapeutic vehicles and biomarkers, but still EV subtypes are not fully characterised. To isolate EVs with few co‐isolated entities, a combination of methods is needed. However, this is time‐consuming and requires large sample volumes, often not feasible in most clinical studies or in studies where small sample volumes are available. Therefore, we compared EVs rendered by five commonly used methods based on different principles from conditioned cell medium and 250 μl or 3 ml plasma, that is, precipitation (ExoQuick ULTRA), membrane affinity (exoEasy Maxi Kit), size‐exclusion chromatography (qEVoriginal), iodixanol gradient (OptiPrep), and phosphatidylserine affinity (MagCapture). EVs were characterised by electron microscopy, Nanoparticle Tracking Analysis, Bioanalyzer, flow cytometry, and LC‐MS/MS. The different methods yielded samples of different morphology, particle size, and proteomic profile. For the conditioned medium, Izon 35 isolated the highest number of EV proteins followed by exoEasy, which also isolated fewer non‐EV proteins. For the plasma samples, exoEasy isolated a high number of EV proteins and few non‐EV proteins, while Izon 70 isolated the most EV proteins. We conclude that no method is perfect for all studies, rather, different methods are suited depending on sample type and interest in EV subtype, in addition to sample volume and budget.

17 November 2013 in Nature Methods
Verified
Journal Article
Closed access
RBRui M M Branca
Rui M M Branca
LOLukas M Orre
Lukas M Orre
HJHenrik J Johansson
Henrik J Johansson
VGViktor Granholm
Viktor Granholm
MHMikael Huss
Mikael Huss
JLJanne Lehtiö
Janne Lehtiö

1 January 2019 in Molecular Cell
Verified
Journal Article
Closed access
LOLukas Minus Orre
Lukas Minus Orre
MVMattias Vesterlund
Mattias Vesterlund
YPYanbo Pan
Yanbo Pan
TATaner Arslan
Taner Arslan
YZYafeng Zhu
Yafeng Zhu
JLJanne Lehtiö
Janne Lehtiö

8 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HJHenrik J. Johansson
Henrik J. Johansson
FSFabio Socciarelli
Fabio Socciarelli
NVNathaniel M. Vacanti
Nathaniel M. Vacanti
MHMads H. Haugen
Mads H. Haugen
YZYafeng Zhu
Yafeng Zhu
JLJanne Lehtiö
Janne Lehtiö
In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

2 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYafeng Zhu
Yafeng Zhu
LOLukas M. Orre
Lukas M. Orre
HJHenrik J. Johansson
Henrik J. Johansson
MHMikael Huss
Mikael Huss
JBJorrit Boekel
Jorrit Boekel
JLJanne Lehtiö
Janne Lehtiö
Proteogenomics enable the discovery of novel peptides (from unannotated genomic protein-coding loci) and single amino acid variant peptides (derived from single-nucleotide polymorphisms and mutations). Increasing the reliability of these identifications is crucial to ensure their usefulness for genome annotation and potential application as neoantigens in cancer immunotherapy. We here present integrated proteogenomics analysis workflow (IPAW), which combines peptide discovery, curation, and validation. IPAW includes the SpectrumAI tool for automated inspection of MS/MS spectra, eliminating false identifications of single-residue substitution peptides. We employ IPAW to analyze two proteomics data sets acquired from A431 cells and five normal human tissues using extended (pH range, 3–10) high-resolution isoelectric focusing (HiRIEF) pre-fractionation and TMT-based peptide quantitation. The IPAW results provide evidence for the translation of pseudogenes, lncRNAs, short ORFs, alternative ORFs, N-terminal extensions, and intronic sequences. Moreover, our quantitative analysis indicates that protein production from certain pseudogenes and lncRNAs is tissue specific.